Pfizer Ltd. — Regulatory Filings 2020

Apr 3, 2020

==> picture [63 x 37] intentionally omitted <==

Limited The Capital, 1802 / 1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

April 2, 2020

Mr. Harshad Naik Mr. Piyush Tanna Listing Compliance Department Chief Manager – Surveillance BSE Limited The National Stock Exchange of India Ltd. P.J.Towers Exchange Plaza, Dalal Street, Fort Plot No. C/1, Block G, Mumbai - 400 001 Bandra-Kurla Complex, Bandra (E) Scrip Code: 500680 Mumbai - 400 051 Scrip Symbol: PFIZER Dear Sirs,

Sub: News Clarification – Pfizer Limited

This refers to your email received by us on April 1, 2020, at 8.22 p.m. seeking clarification on the news item captioned “Setback for Pfizer, US FDA issues warning letter to Company's Vizag plant”, which appeared in the “https://www.zeebiz.com/companies”on April 1, 2020.

We wish to inform you that the above news item does not relate to Pfizer Limited, India. The said news item relates to the manufacturing facility of Pfizer Healthcare India Private Limited, an unlisted Indian subsidiary of Pfizer Inc., USA. Hence, Pfizer Limited India will not be able to comment on the said news item.

We wish to also clarify that the said facility does not supply any products for the India market.

Rest assured, if and when Pfizer Limited makes any announcement regarding any material development in respect of our business, we will ensure that we continue to follow the mandated procedure of informing Stock Exchanges in a timely manner, so as to ensure uniform and simultaneous disclosure to all the investors.

Thanking you,

Yours truly,

For Pfizer Limited

==> picture [91 x 44] intentionally omitted <==

Prajeet Nair Company Secretary

CIN: L24231MH1950PLC008311 contactus.india@pfizer.com